Clinical characteristics and risk factors of young and middle-aged patients with calcified aortic valve disease

doi:10.3969/j.issn.1006-7795.2022.02.004

Abstract

Abstract: Objective To analyze the clinical characteristics of calcific aortic valve disease in the young and middle-aged patients and explore the possible risk factors in this population group. Methods A total of 141 patients with suspected coronary heart disease aged 18-59 who underwent transthoracic echocardiography and coronary angiography from January 2020 to March 2020 were enrolled in the Department of Cardiology, Beijing Anzhen Hospital,Capital Medical University.Baseline data and associated atherosclerotic risk factors were observed in the patients with calcified aortic valve disease and patients with normal aortic valve. Results Compared with adults with normal aortic valves,the patients with calcified aortic valve disease had higher total cholesterol [(4.45±1.00)mmol/L vs (3.93±0.77)mmol/L, P=0.001)], and lower density lipoprotein cholesterol [(2.73±0.76) mmol/L vs (2.42±0.68) mmol/L P=0.016], and the incidence of coronary heart disease was higher (100% vs 90.7% P=0.03).There are risk factors for atherosclerosis in the young and middle-aged patients with calcified aortic valve disease.The less the risk factors of atherosclerosis, the higher the proportion of smoking, hypertension and abnormal glucose metabolism.Logistic regression analysis of risk factors for calcified aortic valve disease in the young and middle-aged adults showed that high total cholesterol was the influencing factor for calcified aortic valve disease in the young and middle-aged adults (P=0.007, OR=4.882, 95%CI: 1.553-15.347). Conclusion The total cholesterol level and low density lipoprotein-cholesterol level of the young and middle-aged patients with calcified aortic valve disease were higher than those with normal aortic valve at the same age, and more patients with coronary heart disease. High total cholesterol level may be the influencing factor of calcified aortic valve disease in the young and middle-aged patients.

Key words: calcific aortic valve disease, transthoracic echocardiography, total cholesterol, low density lipoprotein-cholesterol, risk factors

CLC Number:

Ren Chunqi, Kong Yu, Fu Shenggao, Zhu Zhengyan, Du Xin. Clinical characteristics and risk factors of young and middle-aged patients with calcified aortic valve disease[J]. Journal of Capital Medical University, 2022, 43(2): 187-191.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.02.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I2/187

References

[1] Miller J D, Weiss R M, Heistad D D. Calcific aortic valve stenosis: methods, models, and mechanisms[J]. Circ Res, 2011, 108(11): 1392-1412.
[2] Yi B, Zeng W K, Lv L, et al. Changing epidemiology of calcific aortic valve disease: 30-year trends of incidence, prevalence, and deaths across 204 countries and territories[J]. Aging, 2021, 13(9): 12710-12732.
[3] Nkomo V T, Gardin J M, Skelton T N, et al. Burden of valvular heart diseases: a population-based study[J]. Lancet, 2006, 368(9540): 1005-1011.
[4] Lindman B R, Clavel M A, Mathieu P, et al. Calcific aortic stenosis[J]. Nat Rev Dis Primers, 2016, 2: 16006.
[5] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56.
[6] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4): 311-398.
[7] 诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志, 2016, 44(10): 833-853.
[8] 郭颖, 张瑞生. 中国成人心脏瓣膜病超声心动图规范化检查专家共识[J]. 中国循环杂志, 2021, 36(2): 109-125.
[9] Nishimura R A, Otto C M, Bonow R O, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines[J]. Circulation, 2017, 135(25): e1159-e1195.
[10] 中国结构性心脏病介入治疗进展报告编写组. 中国结构性心脏病介入治疗进展报告2020[J]. 中国循环杂志, 2021, 36(9): 833-840.
[11] Satake S, Arai H. The revised Japanese version of the Cardiovascular Health Study criteria (revised J-CHS criteria)[J]. Geriatr Gerontol Int, 2020, 20(10): 992-993.
[12] Ferreira-González I, Pinar-Sopena J, Ribera A, et al. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area[J]. Eur J Prev Cardiol, 2013, 20(6): 1022-1030.
[13] Rajamannan N M, Evans F J, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update[J]. Circulation, 2011, 124(16): 1783-1791.
[14] Rattazzi M, Bertacco E, Iop L, et al. Extracellular pyrophosphate is reduced in aortic interstitial valve cells acquiring a calcifying profile: implications for aortic valve calcification[J]. Atherosclerosis, 2014, 237(2): 568-576.
[15] Cowell S J, Newby D E, Prescott R J, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis[J]. N Engl J Med, 2005, 352(23): 2389-2397.
[16] Lee S H, Choi J H. Involvement of inflammatory responses in the early development of calcific aortic valve disease: lessons from statin therapy[J]. Anim Cells Syst, 2018, 22(6): 390-399.